MK-0482

N/A

Report date: 2022/02/17 11:00:31

Base Information

Drug NameMK-0482
Drug Alias NameMK-0482
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionLeukocyte immunoglobulin-like receptor subfamily B member 4 inhibitors
TargetsLeukocyte immunoglobulin-like receptor subfamily B member 4
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of Head and NeckSarcoma +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesItaly +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesMerck Sharp & Dohme CorpMerck Sharp & Dohme LLC
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of Head and NeckSarcoma +[4] 
Inactive IndicationsLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A